JPMorgan raised the firm’s price target on Sotera Health (SHC) to $16 from $14 and keeps a Neutral rating on the shares. The company reported a Q3 beat but the litigation overhang remains, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health price target raised to $20 from $19 at Barclays
- Sotera Health Reports Strong Q3 2025 Financial Results
- Sotera Health Earnings Call: Strong Growth Amid Challenges
- Sotera Health reports Q3 adjusted EPS 26c, consensus 22c
- Sotera Health raises FY25 adjusted EPS view to 81c-86c from 75c-82c